Fig. 10.
Vessel density is reduced in PDAC arising in Ptf1a-Cre LSL-KrasG12D p53R172H/+ mice treated with sunitinib. (A) Staining of tumors with endothelial markers CD31 and CD34 in control and sunitinib-treated mice to assess microvessel density. Tumors were also stained with PDGFR-beta to evaluate effect of sunitinib treatment on tumor stroma. Magnification bar (shown in the upper left panel) represents 37.5 µm for the PDGFR-beta panel. CD31 and CD34 panels are depicted at twofold lower magnification; a bar of the same length represents 75 µm. All analyses (PDGFR-beta, CD31, and CD34) were performed on seven sunitinib-treated mice and seven controls (five vehicle, two no treatment). The photomicrographs of invasive tumors immunostained for various antigens is representative of staining multiple tissue sections through each tumor. The staining pattern among mice within each group showed similar patterns except for tumor “f” (see Fig. 11). (B) CD31 and CD34 positive blood vessels were counted in tumors and averaged over four representative regions and plotted with SEM. Analysis of tumor microvessel density in mice receiving NT, no treatment; V, vehicle; or S, sunitinib.